The Treatment and Support Branch, of the National Cancer Institute (NCI) proposes to procure of an IN Cell Analyzer 2200 Imaging System from GE Healthcare Bio-Sciences, Corp. 800 Centennial Avenue, Picataway, NJ, 08854-3911, for the Radiation Oncology Branch at 10 Center Drive, Building 10, Room B3B405, Bethesda, Maryland 20892. Background: The Radiation Oncology Branch conducts research on the biologic and therapeutic effects of radiation administered alone or in combination with chemotehrapeutic agents and targeted agents. An important part of this mission is to understand the effects of radiation on normal and cancerous cells and tissues. The Radiation Biology Branch is focused on research aimed at identifying and incorporating novel approaches to cancer treatment, evaluation, and prevention. These studies require a broad range of capabilities including live cell imaging, FRET studies that allow evaluation of molecular interactions, high throughput automated analysis of various treatment effects, such as DNA damage repair, and high resolution imaging of immunofluorescently stained cells and tissues. The requirement consist of the purchase the IN Cell Analyzer 2200 Imaging System, sensitive wide field cell and tissue imaging system which allows high resolution image acquisition at a rapid pace. Image acquisition and analysis is fully automated to allow screening of large numbers of conditions. Because the device also allows environmental control, cells can be imaged repeatedly over time in optimal conditions for growth or in deficient environments, such as hypoxia. As these measurements are non-destructive, the effects of various treatments on the same living cell or cell population can be measured repeatedly. In addition, the integrated drug delivery ports and fluidics of the INC Cell Analyzer 2200 allow for determining real-time kinetic response of cells to drugs or targeted agents in a single experiment. The IN Cell analyzer 2200 is equipped with a solid state illuminator capable of 7 wavelengths, improving the multi-labeling capabilities beyond standard imaging platforms. The 3D deconvolution properties allow mathematical correction of 3 dimensional populations, such as spheroids or tumor colonies embedded in matrix, a critical part of other research that is ongoing in the Radiation Oncology Branch. The IN Cell Analyzer 2200 will allow investigators to take repeat measurements of cells over time and correlate the molecular properties with using different agents and differing concentrations alone and in combination with radiation therapy. Multiple investigators in both the Radiation Oncology Branch and the Radiation Biology Branch will use the IN Cell Analyzer 2200 to obtain a broad range of data on normal cells and multiple cancer cell lines, including glioma, colorectal, lung, breast, pancreas, and cancer stem cells. This will allow a more rapid and consistent evaluation of potential radiation sensitizers, complex mechanistic studies in vitro in live cells, and a deeper understanding of the molecular events involved in radiation sensitivity and response. NCI will consider offers for the items as listed or their equals. The IN Cell Analyzer 2200 must have a minimum warranty period of one (1) year, including parts and labor. Delivery shall be made F.O.B. Destination, inside delivery, no later than 15 days after contract award to: NIH Radiation Oncology Branch at 10 Center Drive, Building 10, Room B3B405, Bethesda, Maryland 20892. GE Healthcare Bio-Sciences, Corp. is the only party known to NCI that can meet the above requirements. The IN Cell Analyzer 2200 consist of the following: IN Cell 2200 instrument INCA EC Module INCA ASAC 40X.6 Lens INCA 2x.1 OBJ Lens INCA ASAC 60x.7 Lens INCA Liquid Handling INCA 2000 3D decon software INCA 2200 FRET module Investigator 1 ST UPG to NTWK WEB DNLD � Fully automated components including; 8 position emission filter wheel, 4 position objective turret, spherical aberration correction objective collars, and polychroics. � Seven color solid state illumination excitation light source. � Objectives range from 2X to 100X including standard and high NA options. � Large Format 5.5 mp, 16 bit sCMOS camera. � Preview scan feature allows the user to quickly scan a designated area of interest. � Manual microscope mode allows the user to switch objectives, filters, focus, fields of view on the fly as would be conducted in a manual system. � Laser-based, high-speed autofocus for maximum throughput. � Contrast based software autofocus algorithm. � Bright field, temperature/CO2 , and liquid handling options. � Review scanning features which allows for automatic protocol linking, on the fly image analysis. Review scan can be used for rapid primary screening in low magnification, whole well imaging with subsequent hit identification and secondary screening at higher magnification of only the wells of interest (all in a sequential manner in the same plate). � Slide imaging for up to 4 slides at a time. Plate imaging for standard SBS footprint samples (including 6 well to 1536 well as well as custom maps with plate building software). This is not a solicitation for competitive proposals. however, If any other interested parties believes that it can meet the requirements it may submit a Statement of Capabilities. The capability statement and any other information furnished must be in writing, and must contain material in sufficient detail to allow NCI to determine if the party can meet all of the foregoing requirements. Offers must also be accompanied by descriptive literature, warranties, and/or other information that demonstrates that the offer meets all of the foregoing requirements. Capability statements and related materials must be received in this office by 9:00 a.m. EST on August 11, 2014. If you have any specific questions, please submit them in writing to Dawn.Albertini@NIH.gov. Questions will be accepted until August 13, 2014 at 9:00 EST. The determination to compete (or not compete) the proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
